This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Mechanism of Action DosingDosing InformationDose AdjustmentsDrug Interactions Trial Design & EfficacyTrial DesignEfficacy Safety & TolerabilityEPIC-HR Safety DataSmPC Safety DataSupport & ResourcesFrequently Asked QuestionsEducational ResourcesHCP Experience VideosNICE Guidance

Prescribing Information for ▼PAXLOVID (nirmatrelvir / ritonavir) can be found here: Great Britain and Northern Ireland. 

Adverse event reporting information can be found at the bottom of the page. Please note, there are differences between the SmPC for Northern Ireland and the SmPC for Great Britain. Please refer to the appropriate SmPC depending on where you are based.

You could treat COVID-19 from patients' homesKicker PAXLOVID (nirmatrelvir/ritonavir) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.1,2

Paxlovid has a Conditional Marketing Authorisation in Great Britain.*

*A Conditional Marketing Authorisation means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year and the product information will be updated as necessary.
 

 Explore EPIC-HR Clinical Trial Data Safety & Tolerability

Learn more about the safety and tolerability profile of PAXLOVID.

Learn moreLoading
 Dosing Learn about PAXLOVID dosing and potential drug interactions before you prescribe.
 Find out more LoadingPaxlovid is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-191,2Key factors that put a patient at high risk for progression to severe COVID-19 include3,4,5,6: 
  • Patients with Down's Syndrome and other chromosomal disorders known to affect immune competence
  • Solid cancers
  • Solid organ transplant recipients
  • Haematological diseases or HSCT recipients
  • Immune-mediated inflammatory disorders
  • Immune deficiencies 
  • Renal disease
    • Paxlovid is contraindicated in patients with severe renal impairment (GB)1
    • Paxlovid should not be used in patients with severe renal impairment [eGFR < 30 mL/min, including patients with End Stage Renal Disease (ESRD) under haemodialysis] (NI)2
  • Liver disease
    • Paxlovid is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C) (GB)1
    • Paxlovid should not be used in patients with severe hepatic impairment (Child-Pugh Class C) (NI)2
  • Rare neurological and severe complex life-limiting neurodisability conditions
  • HIV / AIDS 
  • Respiratory conditions
  • Neurological disorders

Click here to explore more on the highest risk patients as defined by The Independent Advisory Group Report.  Educational Resources

Explore Paxlovid resources available to support both you and your patients.

 Explore more How PAXLOVID Works


PAXLOVID contains nirmatrelvir, a protease inhibitor specifically designed by Pfizer to target the main SARS-CoV-2 protease and inhibit replication by preventing proteolysis from occurring.1,2

 Find out more LoadingFrequently Asked Questions


Find answers to frequently asked questions on topics that include dosing and potential drug interactions.  

 Frequently Asked Questions Loading
Join us! 

Set up a PfizerPro account to access further materials and resources, and receive communication about medicines and vaccines promoted by Pfizer. 

 Join now
Footnotes:
AIDS; Acquired immunodeficiency syndrome EPIC-HR; Evaluation of Protease Inhibition for COVID-19 in High Risk Patients, HIV; Human Immunodeficiency Virus

References:
1. PAXLOVID GB Summary of Product Characteristics. Pfizer Inc.
2. PAXLOVID NI Summary of Product Characteristics. Pfizer Inc.
3. Coronavirus (COVID-19) - NHS: https://www.nhs.uk/conditions/coronavirus-covid-19/self-care-and-treatments-for-coronavirus/treatments-for-coronavirus Last Accessed July 2023 
4. Defining the highest-risk clinical subgroups upon community infection with SARS-CoV-2 when considering the use of neutralising monoclonal antibodies (nMABs) and antiviral drugs: independent advisory group report. Defining the highest risk clinical subgroups upon community infection with SARS-CoV-2 when considering the use of neutralising monoclonal antibodies (nMABs) and antiviral drugs (updated March 2023) - GOV.UK (www.gov.uk) Last Accessed July 2023
5. Treatments for coronavirus (COVID-19) https://www.nidirect.gov.uk/articles/treatments-coronavirus-covid-19 
6. COVID-19 Community Treatments Northern Ireland (NI) - Frequently Asked Questions. Last updated 5th December 2022 https://www.health-ni.gov.uk/sites/default/files/publications/health/doh-covid-19-community-treatments-ni-faqs.pdf
PP-C1D-GBR-0062. November 2023

Adverse Events
 

Adverse Events should be reported. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​